1
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel (CleverPeptide)
Condition(s):Metastatic Solid Tumor CancerLast Updated:October 13, 2022Recruiting
First in Human: 7262 Clinical Trials, Page 1 of 727
Hide Studies Not Open or Pending
2
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Condition(s):Malignant Tumor; Advanced Solid Tumor; Glioblastoma Multiforme; Metastatic CancerLast Updated:August 10, 2022Recruiting
3
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Condition(s):Locally Advanced/Metastatic HER2 Positive Solid TumorsLast Updated:June 10, 2022Recruiting
4
First in Human Study
Condition(s):Coronary Artery DiseaseLast Updated:October 13, 2022Recruiting
5
First in Human Study of AZD9592 in Solid Tumors
Condition(s):Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck NeoplasmsLast Updated:March 8, 2023Recruiting
6
First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
Condition(s):Advanced Solid Tumor; Endometrial Carcinoma; Hormone Receptor PositiveLast Updated:July 25, 2022Completed
7
A First-in-Human Study of CEE321 in Adult Subjects
Condition(s):Atopic DermatitisLast Updated:October 28, 2022Completed
8
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Condition(s):Urinary Bladder Neoplasms; Colorectal Cancer; Carcinoma, Non-Small-Cell LungLast Updated:March 10, 2023Recruiting
9
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
Condition(s):Heart FailureLast Updated:January 31, 2023Recruiting
10
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Condition(s):Advanced Solid Tumor; Ovarian Cancer; Endometrial Cancer; NSCLCLast Updated:March 6, 2023Recruiting